Integrating Cellvizio® into TaeWoong’s portfolio of therapeutic devices to create the first fully integrated “imaging-to-therapy” solution for EUS-guided pancreatic care
Los Angeles, Paris and Boston, December 3, 2025 – 6:00 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform and TaeWoong Medical USA, a leader in minimally invasive gastrointestinal (GI) diagnostic and therapeutic EUS guided solutions, today announced the signing of an exclusive partnership in the United States to bring physicians and hospitals the industry’s first fully integrated “imaging-to-therapy” solution for pancreatic cystic lesions (PCLs) and related disorders.
Uniting Cellvizio® needle-based, real-time cellular imaging solution with TaeWoong’s proven EUS-guided therapeutic capabilities will create a cohesive clinical program designed to streamline workflow, enhance clinical accuracy and elevate patient outcomes across pancreatic cyst diagnosis, risk stratification, and treatment, thereby better addressing one of the fastest-growing indications challenges in digestive oncology.
The partnership integrates two highly complementary portfolios, enabling a streamlined and co-branded “Pancreatic Cyst Imaging and Management Program – Powered by Cellvizio®” with key features that include:
- Real-time cellular-level, nCLE imaging from Mauna Kea of pancreatic cysts during EUS procedures
- Advanced EUS-guided diagnostic and therapeutic instruments from TaeWoong Medical for treatment — combining diagnostic clarity and interventional capability in one streamlined workflow
- Clinical onboarding, training and ongoing support for physicians and care teams to adopt the integrated platform safely and effectively
- End-to-end patient management — from initial diagnosis and risk stratification through intervention, reducing diagnostic uncertainty, improving patient selection for therapy, and minimizing unnecessary surgeries
- Support for cost-effective care and optimized resource utilization — thanks to improved diagnostic accuracy and reduction of redundant procedures and avoidable resections
It is expected this unified solution will offer clinicians additional clarity and control at each step of EUS-guided care—from initial assessment to therapeutic intervention.
Sacha Loiseau, Ph.D., Chairman & CEO of Mauna Kea Technologies, commented: “The in vivo evaluation of cysts for patients at risk of pancreatic cancer has been a pillar of demand for Cellvizio, supported by proven clinical outcomes and the advocacy of key opinion leaders internationally. However, the scope of our US sales organization limits our commercial reach until now. Our partnership with TaeWoong Medical USA is expected to meaningfully expand Cellvizio’s U.S. footprint by integrating leading therapeutic products with Mauna Kea’s advanced diagnostic capabilities. Moreover, combining TaeWoong’s US commercial infrastructure with a unified value proposition should allow us to scale smarter together. We are thrilled with this alliance as it further validates that Cellvizio has earned the opportunity to be considered a standard of care in a critical clinical application.”
“We are excited to join forces with Mauna Kea Technologies,” said Minsoo Seo, CEO, TaeWoong Medical USA. “Cellvizio’s needle-based microscopic technology is unmatched in its ability to provide real-time cellular-level insights, and its clinical value is recognized by leading centers across the country. Together, we can empower physicians with a complete diagnostic-to-therapeutic solution that elevates patient outcomes and sets a new standard for EUS-driven care.”
